Boston Partners’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$77.5M Sell
641,766
-26,956
-4% -$3.11M 0.08% 229
2025
Q4
$70.4M Sell
668,722
-34,160
-5% -$3.21M 0.07% 239
2025
Q3
$59M Sell
702,882
-61,111
-8% -$5.03M 0.06% 251
2025
Q2
$60.5M Sell
763,993
-9,142
-1% -$727K 0.07% 236
2025
Q1
$69.4M Sell
773,135
-3,658
-0.5% -$342K 0.08% 218
2024
Q4
$77.3M Sell
776,793
-436,367
-36% -$45M 0.09% 211
2024
Q3
$138M Sell
1,213,160
-7,931
-0.6% -$942K 0.16% 191
2024
Q2
$151M Sell
1,221,091
-39,489
-3% -$5.09M 0.19% 177
2024
Q1
$166M Sell
1,260,580
-34,684
-3% -$4.28M 0.2% 175
2023
Q4
$141M Sell
1,295,264
-95,976
-7% -$9.96M 0.19% 181
2023
Q3
$143M Sell
1,391,240
-52,937
-4% -$5.71M 0.2% 158
2023
Q2
$167M Sell
1,444,177
-133,036
-8% -$15.1M 0.22% 142
2023
Q1
$168M Sell
1,577,213
-36,290
-2% -$3.92M 0.23% 142
2022
Q4
$179M Sell
1,613,503
-101,192
-6% -$10.3M 0.24% 136
2022
Q3
$148M Sell
1,714,695
-101,950
-6% -$9.1M 0.22% 139
2022
Q2
$166M Sell
1,816,645
-68,838
-4% -$6.1M 0.23% 141
2022
Q1
$155M Sell
1,885,483
-57,297
-3% -$4.52M 0.19% 164
2021
Q4
$149M Sell
1,942,780
-846,752
-30% -$67.4M 0.18% 173
2021
Q3
$210M Buy
2,789,532
+151,945
+6% +$11.6M 0.27% 135
2021
Q2
$205M Buy
2,637,587
+36,427
+1% +$2.71M 0.26% 132
2021
Q1
$191M Buy
2,601,160
+765,411
+42% +$56.5M 0.26% 131
2020
Q4
$143M Sell
1,835,749
-3,204,698
-64% -$245M 0.22% 148
2020
Q3
$399M Sell
5,040,447
-518,992
-9% -$40.7M 0.73% 39
2020
Q2
$410M Sell
5,559,439
-1,182,503
-18% -$89M 0.75% 39
2020
Q1
$495M Buy
6,741,942
+3,578,988
+113% +$281M 0.98% 21
2019
Q4
$275M Sell
3,162,954
-448,601
-12% -$36.8M 0.36% 88
2019
Q3
$290M Sell
3,611,555
-186,259
-5% -$14.9M 0.39% 79
2019
Q2
$304M Sell
3,797,814
-189,108
-5% -$14.5M 0.4% 85
2019
Q1
$316M Sell
3,986,922
-133,894
-3% -$10M 0.42% 71
2018
Q4
$300M Sell
4,120,816
-9,937,401
-71% -$702M 0.43% 70
2018
Q3
$952M Sell
14,058,217
-1,189,790
-8% -$75.8M 1.11% 16
2018
Q2
$883M Sell
15,248,007
-389,931
-2% -$22M 1.06% 17
2018
Q1
$813M Sell
15,637,938
-2,349,754
-13% -$127M 0.98% 19
2017
Q4
$966M Sell
17,987,692
-1,642,264
-8% -$91M 1.14% 13
2017
Q3
$1.2B Buy
19,629,956
+152,740
+0.8% +$9.26M 1.48% 5
2017
Q2
$1.19B Sell
19,477,216
-1,414,681
-7% -$86.1M 1.51% 5
2017
Q1
$1.27B Buy
20,891,897
+524,499
+3% +$31.8M 1.62% 6
2016
Q4
$1.14B Buy
20,367,398
+1,016,309
+5% +$59.5M 1.5% 7
2016
Q3
$1.15B Sell
19,351,089
-596,856
-3% -$34.9M 1.61% 4
2016
Q2
$1.1B Buy
19,947,945
+3,831,109
+24% +$204M 1.58% 4
2016
Q1
$814M Buy
16,116,836
+783,358
+5% +$38.4M 1.2% 10
2015
Q4
$773M Sell
15,333,478
-2,116,255
-12% -$107M 1.11% 16
2015
Q3
$822M Buy
17,449,733
+1,822,475
+12% +$96.8M 1.25% 12
2015
Q2
$849M Buy
15,627,258
+790,141
+5% +$44.3M 1.22% 12
2015
Q1
$814M Buy
+14,837,117
New +$840M 1.21% 13

Other funds holding MRK

Boston Partners's MRK Position: Q1 2026 in Review

Boston Partners reduced its Merck (MRK) stake by 4% in Q1 2026, selling an estimated $3.11M and leaving 641,766 shares worth $77.5M. The position accounts for 0.08% of the portfolio, ranked #229.

Boston Partners first reported a position in MRK in Q1 2015 and has held it in 45 quarters since. The position peaked at $1.27B in Q1 2017. 3,779 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Boston Partners held 641,766 shares of Merck worth $77.5M as of Q1 2026.
  • Boston Partners sold 26,956 Merck shares in Q1 2026, an estimated $3.11M.
  • Merck made up 0.08% of Boston Partners's portfolio in Q1 2026, its #229 holding.
  • Boston Partners first reported a position in Merck in Q1 2015 and has held it in 45 quarters since.
  • Boston Partners's Merck position peaked at $1.27B in Q1 2017.
  • 3,779 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Boston Partners's 13F filing for Q1 2026, filed 11 May 2026.